Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2012

Open Access 01-12-2012 | Research

Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening

Published in: Journal of Ovarian Research | Issue 1/2012

Login to get access

Abstract

Background

Ovarian cancer stem cells are characterized by self-renewal capacity, ability to differentiate into distinct lineages, as well as higher invasiveness and resistance to many anticancer agents. Since they may be responsible for the recurrence of ovarian cancer after initial response to chemotherapy, development of new therapies targeting this special cellular subpopulation embedded within bulk ovarian cancers is warranted.

Methods

A high-throughput screening (HTS) campaign was performed with 825 compounds from the Mechanistic Set chemical library [Developmental Therapeutics Program (DTP)/National Cancer Institute (NCI)] against ovarian cancer stem-like cells (CSC) using a resazurin-based cell cytotoxicity assay. Identified sets of active compounds were projected onto self-organizing maps to identify their putative cellular response groups.

Results

From 793 screening compounds with evaluable data, 158 were found to have significant inhibitory effects on ovarian CSC. Computational analysis indicates that the majority of these compounds are associated with mitotic cellular responses.

Conclusions

Our HTS has uncovered a number of candidate compounds that may, after further testing, prove effective in targeting both ovarian CSC and their more differentiated progeny.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60: 277–300. 10.3322/caac.20073PubMedCrossRef
2.
Herzog TJ: Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004, 10: 7439–7449. 10.1158/1078-0432.CCR-04-0683PubMedCrossRef
3.
Bapat SA, Mali AM, Koppikar CB, Kurrey NK: Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005, 65: 3025–3029.PubMed
4.
Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008, 68: 4311–4320. 10.1158/0008-5472.CAN-08-0364PubMedCentralPubMedCrossRef
5.
Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009, 28: 209–218. 10.1038/onc.2008.374PubMedCrossRef
6.
Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I, Mor G: Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009, 8: 158–166. 10.4161/cc.8.1.7533PubMedCentralPubMedCrossRef
7.
8.
9.
10.
Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138: 645–659. 10.1016/j.cell.2009.06.034PubMedCrossRef
11.
Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, Squire JA, Smith A, Dirks P: Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009, 4: 568–580. 10.1016/j.stem.2009.03.014PubMedCrossRef
12.
Visnyei K, Onodera H, Damoiseaux R, Saigusa K, Petrosyan S, De Vries D, Ferrari D, Saxe J, Panosyan EH, Masterman-Smith M, Mottahedeh J, Bradley KA, Huang J, Sabatti C, Nakano I, Kornblum HI: A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Mol Cancer Ther 2011, 10: 1818–1828. 10.1158/1535-7163.MCT-11-0268PubMedCentralPubMedCrossRef
13.
Wang L, Mezencev R, Bowen NJ, Matyunina LV, McDonald JF: Isolation and characterization of stem-like cells from a human ovarian cancer cell line. Mol Cell Biochem 2011, 363: 257–268.PubMedCrossRef
14.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100: 3983–3988. 10.1073/pnas.0530291100PubMedCentralPubMedCrossRef
15.
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature 2004, 432: 396–401. 10.1038/nature03128PubMedCrossRef
16.
Levina V, Marrangoni AM, De Marco R, Gorelik E, Lokshin AE: Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008, 3: e3077. 10.1371/journal.pone.0003077PubMedCentralPubMedCrossRef
17.
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1: 555–567. 10.1016/j.stem.2007.08.014PubMedCentralPubMedCrossRef
18.
Holbeck SL: Update on NCI in vitro drug screen utilities. Eur J Cancer 2004, 40: 785–793. 10.1016/j.ejca.2003.11.022PubMedCrossRef
19.
20.
21.
Hsiao AY-C: 3D spheroid culture systems for metastatic prostate cancer dormancy studies and anti-cancer therapeutics development. Universtiy of Michigan: (Doctoral dissertation). Retrieved from ProQuest Dissertations & Theses (ID 896131060); 2011.
22.
Dong Y, Tan OL, Loessner D, Stephens C, Walpole C, Boyle GM, Parsons PG, Clements JA: Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res 2010, 70: 2624–2633. 10.1158/0008-5472.CAN-09-3415PubMedCrossRef
23.
Inglese J, Shamu CE, Guy RK: Reporting data from high-throughput screening of small-molecule libraries. Nat Chem Biol 2007, 3: 438–441. 10.1038/nchembio0807-438PubMedCrossRef
24.
Holm S: A simple sequentially rejective multiple test procedure. Scand J Statist 1979, 6: 65–70.
25.
26.
27.
28.
Huang R, Wallqvist A, Thanki N, Covell DG: Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action. Pharmacogenomics J 2005,5(6):381–399. 10.1038/sj.tpj.6500331PubMedCrossRef
29.
30.
Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, Falkson G, Davis TE, Fazzini E, Cheuvart B, Horton J: Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest 1992, 10: 1–9.PubMedCrossRef
31.
Fraschini A, Bottone MG, Scovassi AI, Denegri M, Risueño MC, Testillano PS, Martin TE, Biggiogera M, Pellicciari C: Changes in extranucleolar transcription during actinomycin D-induced apoptosis. Histol Histopathol 2005, 20: 107–117.PubMed
32.
Lee TJ, Jung EM, Lee JT, Kim S, Park JW, Choi KS, Kwon TK: Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther 2006, 5: 2737–2746. 10.1158/1535-7163.MCT-06-0426PubMedCrossRef
33.
Lewis JL Jr: Chemotherapy of gestational choriocarcinoma. Cancer 1972, 30: 1517–1521. 10.1002/1097-0142(197212)30:6<1517::AID-CNCR2820300616>3.0.CO;2-8PubMedCrossRef
34.
Frei E 3rd: The clinical use of actinomycin. Cancer Chemother Rep 1974, 58: 49–54.PubMed
35.
Kennedy BJ: Mithramycin therapy in advanced testicular neoplasms. Cancer 1970, 26: 755–766. 10.1002/1097-0142(197010)26:4<755::AID-CNCR2820260403>3.0.CO;2-UPubMedCrossRef
36.
Perlia CP, Gubisch NJ, Wolter J, Edelberg D, Dederick MM, Taylor SG 3rd: Mithramycin treatment of hypercalcemia. Cancer 1970, 25: 389–394. 10.1002/1097-0142(197002)25:2<389::AID-CNCR2820250217>3.0.CO;2-XPubMedCrossRef
37.
Pratt WB, Ruddon RW, Ensminger WD, Maybaum J: The anticancer drugs. 2nd edition. New York: Oxford University Press; 1994.
38.
Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, Silva EG, Wharton JT: Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990, 8: 715–720.PubMed
39.
Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR, Gudkov AV: Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 2005, 102: 17448–17453. 10.1073/pnas.0508888102PubMedCentralPubMedCrossRef
40.
Preet R, Mohapatra P, Mohanty S, Sahu SK, Choudhuri T, Wyatt MD, Kundu CN: Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. Int J Cancer 2012,130(7):1660–1670. 10.1002/ijc.26158PubMedCrossRef
41.
Van Dyke K, Lantz C, Szustkiewicz C: Quinacrine: mechanisms of antimalarial action. Science 1970, 169: 492–493. 10.1126/science.169.3944.492PubMedCrossRef
42.
Koldsland S, Svennevig JL, Lehne G, Johnson E: Chemical pleurodesis in malignant pleural effusions: a randomised prospective study of mepacrine versus bleomycin. Thorax 1993, 48: 790–793. 10.1136/thx.48.8.790PubMedCentralPubMedCrossRef
43.
Diehn M, Clarke MF: Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 2006, 98: 1755–1757. 10.1093/jnci/djj505PubMedCrossRef
44.
Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5: 275–284. 10.1038/nrc1590PubMedCrossRef
45.
Wicha MS, Liu S, Dontu G: Cancer stem cells: an old idea–a paradigm shift. Cancer Res 2006, 66: 1883–1890. 10.1158/0008-5472.CAN-05-3153PubMedCrossRef
46.
Lobo NA, Shimono Y, Qian D, Clarke MF: The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007, 23: 675–699. 10.1146/annurev.cellbio.22.010305.104154PubMedCrossRef
47.
Rabow AA, Shoemaker RH, Sausville EA, Covell DG: Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J Med Chem 2002, 45: 818–840. 10.1021/jm010385bPubMedCrossRef
48.
Shoemaker RH: The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006, 6: 813–823. 10.1038/nrc1951PubMedCrossRef
Metadata
Title
Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening
Publication date
01-12-2012
Published in
Journal of Ovarian Research / Issue 1/2012
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/1757-2215-5-30

Other articles of this Issue 1/2012

Journal of Ovarian Research 1/2012 Go to the issue

Research

Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples

Research

Heart type fatty acid binding protein response and subsequent development of atherosclerosis in insulin resistant polycystic ovary syndrome patients

Research

Gonadotropin treatment augments postnatal oogenesis and primordial follicle assembly in adult mouse ovaries?

Brief communication

Transvaginal ultrasound ovarian diathermy: sheep as an experimental model

Research

GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer

Research

Discovery of dachshund 2 protein as a novel biomarker of poor prognosis in epithelial ovarian cancer